Not independent
Tenure on this board
4.8 yrs
Also a director at
Arbutus Biopharma Corp (ABUS)
Meeting calendar
ROIV · Annual meeting · Wednesday, September 10, 2025
Roivant Sciences Ltd
3 nominees · 3 ballot items.
Three proposals are up for a vote at the Roivant Sciences Ltd. 2025 Annual General Meeting: (1) election of three Class I directors nominated by management; (2) ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending March 31, 2026; (3) non-binding advisory vote to approve named executive officer compensation.
Market cap
$25.2B
1Y TSR
+172.9%
Board grade
B
Record date
Jul 17, 2025
Filing
DEF 14A
Meeting concluded · Sep 10, 2025
Follow how the vote landed and what changed on Roivant Sciences Ltd’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of three Class I directors
ManagementBoard: FORElection of Matthew Gline, Keith Manchester and Melissa Epperly to serve as Class I directors for three-year terms and until their successors are elected and qualified (or earlier death, resignation or removal).
- 2
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify Ernst & Young LLP as Roivant's independent registered public accounting firm for the fiscal year ending March 31, 2026, and authorize the Board to set EY's remuneration for that year.
- 3
Non-Binding, Advisory Vote to Approve the Compensation of Named Executive Officers
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of Roivant's named executive officers.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
4.8 yrs
Independent
Tenure on this board
4.0 yrs
Also a director at
Nautilus Biotechnology Inc (NAUT)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | MORGAN STANLEY | 6.7% | 48,239,361 | $1.3B |
| 2 | FMR LLC | 6.6% | 47,324,474 | $1.3B |
| 3 | FMR LLC | 4.2% | 30,466,652 | $844M |
| 4 | BlackRock, Inc. | 3.7% | 26,949,884 | $747M |
| 5 | QVT Financial LPActivist | 3.5% | 25,161,237 | $697M |
| 6 | UBS Group AG | 2.9% | 20,727,487 | $574M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 20,680,572 | $573M |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8% | 19,838,698 | $550M |
| 9 | STATE STREET CORP | 2.3% | 16,186,613 | $448M |
| 10 | BlackRock, Inc. | 1.8% | 12,949,567 | $359M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Roivant Sciences Ltd’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Steris PLCSTE
Annual meeting·Jul 31, 2026·$20.6B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Catalyst Pharmaceuticals IncCPRX
Special meeting·Jul 8, 2026·$3.8B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.4B
Reference
Frequently asked questions
- When is the Roivant Sciences Ltd 2025 annual meeting?
- Roivant Sciences Ltd (ROIV) holds its 2025 annual shareholder meeting on Wednesday, September 10, 2025.
- What is the record date for the Roivant Sciences Ltd 2025 meeting?
- The record date for the Roivant Sciences Ltd 2025 meeting is Thursday, July 17, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Roivant Sciences Ltd's 2025 meeting?
- The board is presenting 3 director nominees at the Roivant Sciences Ltd 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Roivant Sciences Ltd 2025 meeting?
- Shareholders will vote on 3 proposals at the Roivant Sciences Ltd 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.